Managing antipsychotic medications in schizophrenia: comprehensive assessment and personalized care to improve clinical outcomes and reduce costs.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Novel nanostructured lipid carriers with lurasidone hydrochloride for intranasal administration for improved bioavailability.Therapeutic delivery · 2025
   Article
2. Review: Influence of the CYP450 Genetic Variation on the Treatment of Psychotic Disorders.Journal of clinical medicine · 2021
   Review
3. Application of a Pharmacogenetics-Based Precision Medicine Model (5SPM) to Psychotic Patients That Presented Poor Response to Neuroleptic Therapy.Journal of personalized medicine · 2020
   Article

Corrections and comments

• Comment on
  Antipsychotic treatment and the risk of hip fracture in subjects with schizophrenia: a 10-year population-based case-control study.2015

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as